A compound of formula (Ia), wherein L 1 is a linker selected from a bond or -C 1 -C 2 -alkylene, wherein R 7 is a ring selected from among -C 3 -C 8 -cycloalkyl, -C 3 -C 8 -heterocyclyl, -C 5 -C 10 -aryl, and -C 5 -C 10 -heteroaryl, wherein the ring R 7 is optionally substituted with one or more groups selected from among -CF 3, -C 1 -C 6 -alkyl, -O-CF 3, -CN, -O-C 1 -C 6 -alkyl, -C 1 -C 6 -alkenyl, and -C 1 -C 6 -alkynyl, and -halogen, or wherein the ring R 7 is optionally substituted with one or more groups selected from among -C 5 -C 10 -aryl, -C 5 -C 10 -heteroaryl, -C 3 -C 8 -cycloalkyl, -C 3 -C 8 -heterocyclyl, optionally being substituted by one or more groups selected from among -OH, -NH 2, -C 1 -C 4 -alkyl, -O-C 1 -C 6 -alkyl, -CN, -CF 3, -OCF 3, halogen, and =O, or wherein the ring R 7 is optionally further bi-valently substituted on two neighbouring ring atoms, such that an annellated ring is formed by one or more groups selected from among -C 1 -C 6 -alkylene, -C 2 -C 6 -alkenylene and -C 4 -C 6 -alkynylene, in which one or two carbon centers may optionally be replaced by 1 or 2 hetero atoms selected from N, O and S, the bivalent group being optionally substituted by one or more groups selected from -OH, -NH 2, -C 1 -C 4 -alkyl, -O-C 1 -C 6 -alkyl, -CN, -CF 3, -OCF 3, halogen, and =O, wherein R 2 is selected from among -H, -halogen, -CN, -O-C 1 -C 4 -alkyl, -C 1 -C 4 -alkyl, -CH=CH 2, -C≡CH, -cyclopropyl, -CF 3, -OCF 3, -OCF 2 H, and -OCFH 2; wherein R 5 denotes a group of the structure -L 2 -R 18, wherein L 2 is a group selected from among -NH-, and -N(CH 3)-, wherein R 18 is -C 6 -heterocyclyl comprising 1 hetero atom selected from O, wherein R 18 is optionally substituted by -O-CH 3; or wherein R 5 denotes a group of the structure -N(R 20,R 20'), wherein R 20 and R 20' together form a -C 4 -C 5 -alkylene group such that a ring is formed, wherein such ring is optionally substituted with one or more groups selected from -N(C 0 -C 1 -alkyl)-SO 2 -CH 3; as well as in form of their acid addition salts with pharmacologically acceptable acids. wherein L 1 is a linker selected from a bond or -C 1 -C 2 -alkylene, wherein R 7 is a ring selected from among -C 3 -C 8 -cycloalkyl, -C 3 -C 8 -heterocyclyl, -C 5 -C 10 -aryl, and -C 5 -C 10 -heteroaryl, wherein the ring R 7 is optionally substituted with one or more groups selected from among -CF 3, -C 1 -C 6 -alkyl, -O-CF 3, -CN, -O-C 1 -C 6 -alkyl, -C 1 -C 6 -alkenyl, and -C 1 -C 6 -alkynyl, and -halogen, or wherein the ring R 7 is optionally substituted with one or more groups selected from among -C 5 -C 10 -aryl, -C 5 -C 10 -heteroaryl, -C 3 -C 8 -cycloalkyl, -C 3 -C 8 -heterocyclyl, optionally being substituted by one or more groups selected from among -OH, -NH 2, -C 1 -C 4 -alkyl, -O-C 1 -C 6 -alkyl, -CN, -CF 3, -OCF 3, halogen, and =O, or wherein the ring R 7 is optionally further bi-valently substituted on two neighbouring ring atoms, such that an annellated ring is formed by one or more groups selected from among -C 1 -C 6 -alkylene, -C 2 -C 6 -alkenylene and -C 4 -C 6 -alkynylene, in which one or two carbon centers may optionally be replaced by 1 or 2 hetero atoms selected from N, O and S, the bivalent group being optionally substituted by one or more groups selected from -OH, -NH 2, -C 1 -C 4 -alkyl, -O-C 1 -C 6 -alkyl, -CN, -CF 3, -OCF 3, halogen, and =O, wherein R 2 is selected from among -H, -halogen, -CN, -O-C 1 -C 4 -alkyl, -C 1 -C 4 -alkyl, -CH=CH 2, -C≡CH, -cyclopropyl, -CF 3, -OCF 3, -OCF 2 H, and -OCFH 2; wherein R 5 denotes a group of the structure -L 2 -R 18, wherein L 2 is a group selected from among -NH-, and -N(CH 3)-, wherein R 18 is -C 6 -heterocyclyl comprising 1 hetero atom selected from O, wherein R 18 is optionally substituted by -O-CH 3; or wherein R 5 denotes a group of the structure -N(R 20,R 20'), wherein R 20 and R 20' together form a -C 4 -C 5 -alkylene group such that a ring is formed, wherein such ring is optionally substituted with one or more groups selected from -N(C 0 -C 1 -alkyl)-SO 2 -CH 3;